Chinese government confirms regulatory approval for iTrack™

6 June 2017

Highlight: Chinese government confirms regulatory approval for iTrack™ until 23 May 2022 – the only MIGS device to treat glaucoma approved in this market Adelaide, Australia, 6 June 2017– Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced an extension of regulatory approval in China for its minimally invasive glaucoma surgery (MIGS) device, Ellex iTrack™. On 2 June 2017, Ellex received advice from the Chinese government that the Ellex iTrack™ device’s approval for sale in China has been extended until 23 May 2022. Ellex iTrack™ is the only MIGS device approved for sale in China. China is a key market segment for Ellex iTrack™ and the Company is…

Read more

Acquisition of iTrack™ royalty commitment removes all royalty payments on future sales, with 100% of all future iTrack™ revenue now attributed to Ellex

30 May 2017

Adelaide, Australia, 30 May 2017 Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced that it has acquired the future iTrack™ royalty commitment from ISCI Holdings Inc., the original vendor of the iTrack™ business. Ellex has agreed to purchase all future royalties for its proprietary iTrack™ device at a total cost of US$2.15 million. This includes an initial payment of US$0.650 million made on 25 May 2016. The final instalment of US$1.5m will be made on 15 September 2017. The Company believes that the acquisition price represents good value at a time when it prepares to accelerate global sales and marketing efforts for the iTrack™ product. The original…

Read more

Ellex iTrack MIGS Technology to Feature at 2017 American Society of Cataract and Refractive Surgery

5 May 2017

Adelaide, Australia, 5 May 2017 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced that its proprietary iTrack™ minimally invasive glaucoma surgery (MIGS) technology will figure in the official scientific program of the annual American Society of Cataract and Refractive Surgery (ASCRS), Los Angeles, 5-9 May 2017. This will also coincide with the release of positive, interim 24-month ABiC™ case series data by Dr. Mark J. Gallardo (El Paso Eye Surgeons, Texas, USA). ASCRS 2017 The annual ASCRS meeting is the preeminent scientific and industry event for cataract and refractive surgeons and medical personnel in the ophthalmic industry. Key physician presentations and courses featuring Ellex iTrack™ and…

Read more

Financial Report for Half-Year Ended 31 December 2016

27 February 2017

Highlights: Total sales of $34.3m up on prior comparable period on a constant currency basis Ellex iTrack business segment global sales of $3.6m up 37% on prior comparable period on a constant currency basis with acceleration of sales growth in USA since 31 December 2016 EBITDA of $3.2m up on prior comparable period after adjusting for investments in high-growth Ellex iTrack and 2RT for early macular degeneration business segments Approval received from Australian Therapeutic Goods Administration (TGA) on 17 February 2017 of new laser and ultrasound production facility at Mawson Lakes, South Australia Enhanced reporting of the business into three segments; Core Laser and Ultrasound, Ellex iTrack and 2RT for Early AMD provides additional visibility of high growth business segments…

Read more

Ellex Trading Update for the Six Months Ended 31 December 2016

2 February 2017

Adelaide, Australia, 2 February 2017 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced that its sales revenue for the six months ended 31 December 2016 will be similar to the prior corresponding period (PCP). The primary cause of the lack of sales growth during the last half year period was the shift of management focus to the establishment of Ellex’s new manufacturing facility at Mawson Lakes, Adelaide at the expense of meeting production challenges resulting in production capacity limitations and a consequent inability to deliver core Laser and Ultrasound product against targets. This resulted in a significant customer order backlog as at 31 December 2016, which…

Read more

Ellex iTrack™ commencement of clinical training in China

15 December 2016

Adelaide, Australia, 15 December 2016 – Ellex Medical Lasers Limited (ASX: ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced that clinical training of physicians in China in the use of the Ellex iTrack™ minimally invasive glaucoma surgery (MIGS) device has commenced. The Ellex iTrack™ is the only MIGS device in the world currently approved by the Chinese medical device regulatory authority for sale in China. First clinical training in ABiC with Ellex iTrack™ This is the first program of clinical training of physicians in the ab interno canaloplasty (ABiC) technique. This program is being conducted at leading hospitals and teaching institutions in Shanghai and Beijing during 12-17 December 2016. “To date,…

Read more

Ellex Raises $10.3 million via Placement to Pursue iTrack™ Growth Opportunities

1 December 2016

Adelaide, Australia, 1 December 2016 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced the that it has raised $10.3m in a placement of shares with Australia and New Zealand investors. These funds will be used as follows: Accelerate sales growth of Ellex iTrack with the development of US-headquartered minimally invasive glaucoma surgery device (MIGS) business focussed on growth the USA and China. In the USA this will include building a sales force of at least 15 people over the next 6 to 9 months up from 6 at the moment. Further the pipeline of products associated with the iTrack to underpin its role as an emerging…

Read more

Results of 2016 Annual General Meeting Incorporating Proxy Results

23 November 2016

Adelaide, Australia, 23 November 2015 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, confirms in accordance with Listing Rule 3.13.2, the results for each of the resolutions put to the Annual General Meeting held at 2:00 pm on Wednesday 23 November 2016 was as follows: Ordinary Business Resolution 2 – Re-election of Rahmon Coupe as a Director The instructions given to validly appointed proxies in respect of the Resolution were as follows: [align-center]ForAgainstOpenAbstain40,517,312202,436683,47246,259 Result: Resolution Carried by a show of hands Resolution 3 – Ratification of Prior Share Issue Placement for Purpose of Listing Rule 7.4: Reset of 15% Threshold The instructions given to validly appointed proxies in…

Read more

Ellex Announces Increase in USA Reimbursement for iTrack Procedures

10 November 2016

Adelaide, Australia, 10 November 2016 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced important progress on its expansion of sales of the Ellex iTrack minimally invasive glaucoma surgery (MIGS) device. Recap on iTrack and the Minimally Invasive Glaucoma Surgery (MIGS) Device Market iTrack is a single-use, minimally invasive glaucoma surgery (MIGS) device used to comprehensively restore the natural outflow pathways in open-angle glaucoma patients who are no longer responding to SLT or pharmaceuticals. iTrack, used in simple, fast ab interno procedure, accesses, catheterizes, and viscodilates the 360 degrees of the eye’s natural drainage system. The iTrack procedure (known as “ABiC”) can be performed either as a…

Read more

Ellex to Launch New Ophthalmic Ultrasound Device

6 September 2016

Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced that it will launch a new addition to its diagnostic ultrasound portfolio at the 2016 congress of the European Society of Cataract and Refractive Surgeons (ESCRS), 10-14 September, Denmark. The Eye One™ is a portable ultrasound platform that provides full coverage of all ocular examination and measurement modes. The system offers the same power and precision imaging as Ellex’s industry-leading Eye Cubed™ ultrasound system, built into a compact, portable platform. Eye One™ is approximately two-thirds the size of Eye Cubed™ and 40% of the weight. It is designed for retinal specialists and cataract and refractive specialists, as well as…

Read more

Ellex Reports Full Year FY16 Audited Results

26 August 2016

Highlights: • Sales of $72.9m up 16% on prior corresponding period • Profit before tax of $4.2m up 59% on prior corresponding period Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for diagnosis and treatment of eye disease, today announced an operating profit before tax (PBT) of $4.2m for the year ended 30 June 2016. This represents a 59% improvement on the PBT reported for the year ended 30 June 2015. “This is the fourth consecutive year of revenue and profit growth both in absolute terms and as a percentage of sales” commented Ellex CEO Tom Spurling. The improved sales has three components, namely: • Positive impact of organic growth in sales of Ellex-branded product in USA,…

Read more

Ellex awarded $2.5m Federal Government Grant

26 August 2016

Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced it has been awarded a grant of $2.5 million from the Federal Government’s “Next Generation Manufacturing Investment Programme”. The grant award was announced by the Minister for Industry, Innovation & Science, the Hon. Greg Hunt MP. “We are very pleased to be awarded this grant. It will facilitate the investment in advanced equipment and systems we need to expand our manufacturing capacity to satisfy the rapidly growing international demand in our ophthalmic lasers and ultrasound.” commented Ellex CEO Tom Spurling. The award of this grant corresponds with Ellex’s manufacturing site relocation from the Adelaide CBD to Mawson Lakes, 15km…

Read more

Trading Update for the Year Ended 30 June 2016

28 July 2016

Financial Highlights: Global sales of A$72.9m, an increase of 16% on the prior comparable period Estimated profit before tax up from A$2.6 million to A$4.2 million, a 61% increase Ellex Medical Lasers Limited (ASX:ELX), a world leader in medical technologies for the diagnosis and treatment of eye disease, today announced that it expects to report a profit before tax of approximately A$4.2 million for the year ended 30 June 2016. The result will be a material increase in the profit before tax of A$2.6 million reported for the year ended 30 June 2015. Revenue Group revenue for the year ended 30 June 2016 is expected to be approximately A$72.9 million, a A$10.1 million (16%) increase compared to the prior corresponding…

Read more

Ellex Secures China FDA Approval for Ophthalmic Treatment Lasers

15 June 2016

Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced that the China Food and Drug Administration (China FDA) has granted regulatory approval for the Company’s complete portfolio of glaucoma, vitreous floaters and secondary cataract treatment lasers (collectively referred to as the “YAG laser” portfolio) in the Chinese market. Previously, sales of the Company’s YAG lasers in China had been restricted to a specific limited market. With the Company’s proprietary YAG laser portfolio now available to all ophthalmologists in China, the approval by China FDA is expected to lead directly to increased sales in China during the 2017 financial year. “The approval process required a significant investment, with resources…

Read more

Ellex iTrack for Glaucoma Demonstrates Efficacy and Safety at 12 Months

6 May 2016

Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced that positive 12-month case series data for the Company’s proprietary ABiC™ minimally invasive glaucoma surgery (MIGS) procedure will be presented at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) meeting in New Orleans, 6-9 May 2016. The results show that ABiC™ can effectively reduce intraocular pressure (IOP) and medication dependence in glaucoma patients with minimal complications. Furthermore, based on these results, ABiC™ may potentially offer better clinical outcomes than any other currently available MIGS procedure. A restorative glaucoma surgery, ABiC™ uses Ellex’s proprietary iTrack™ microcatheter to comprehensively open up all components of the eye’s natural outflow system…

Read more

Ellex Financial Report for Half-Year ended 31 December 2015

26 February 2016

Highlights: Revenues up by 13% on pcp to $34.8m Profit before tax up by 36% on pcp to $1.8m Fourth consecutive increase in first half profits and margins Growth expected to continue in second half and beyond Adelaide, Australia, 26 February 2016 – Ellex Medical Lasers Limited (ASX:ELX), a world leader in medical technologies for the diagnosis and treatment of eye disease, today released its financial results for the half year ended 31 December 2015. Ellex reported a profit before tax of $1.8m compared with $1.3m in the prior corresponding period. The result was struck on revenue of $34.8m which was 13% higher ($4.1m) than the prior corresponding period. The revenue increase has 3 separate components: Positive impact of organic…

Read more

Trading Update for the Half-Year Ended 31 December 2015

29 January 2016

Financial Highlights: – Global sales of A$34.8m, an increase of 13% on the prior comparable period – Estimated profit before tax up from A$1.3 million to A$1.8 million, a 38% increase – Adjusted for new operating expenses that will benefit future periods, estimated profit before tax is up 71% Ellex Medical Lasers Limited (ASX:ELX), a world leader in medical technologies for the diagnosis and treatment of eye disease, today announced that it expects to report a profit before tax of approximately A$1.8 million for the six months ended 31 December 2015. The result will be a material increase in the profit before tax of A$1.3 million reported for the six months ended 31 December 2014. Revenue Group revenue for the…

Read more

Ellex Expands Production Facilities to Meet Anticipated Demand

22 January 2016

Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for diagnosis and treatment of eye disease, today announced that it has entered into a conditional contract to acquire a building in the northern suburbs of Adelaide, South Australia which will provide additional production capacity in order to meet increasing demand for its ophthalmic laser and ultrasound products. “Demand for our products is strong and we expect it to remain so for the foreseeable future. We moved into our current premises, in the City of Adelaide, 15 years ago and have now outgrown that site. This new building provides us with 50% more floor space and there is room for further expansion on the site, if required, by extending…

Read more

Ellex iTrack™ Achieves Further Market Traction and will be Featured at Major US Tradeshow

4 November 2015

Ellex announced that its Ab Interno Canaloplasty procedure (dubbed ABiC™), performed with the Company’s patented iTrack™ microcatheter, will for the first time feature in the official scientific program of the American Academy of Ophthalmology (AAO). The AAO is the pre-eminent ophthalmic conference globally and attracts approximately 10,000 ophthalmologists each year.

Read more

Ellex Expands into Fast-Growing Minimally Invasive Glaucoma Surgery Device Market

1 October 2015

Ellex announced following successful clinical investigations and based on prior three-year trial data, it has entered the fast-growing Minimally Invasive Glaucoma Surgery (MIGS) device market with the launch of its new “ab-interno” Canaloplasty surgical procedure.

Read more

Ellex releases first case study results for 2RT at major tradeshow

14 September 2015

Ellex released its first case study results from commercial users of its 2RT™ retinal rejuvenation laser.

Read more

ELX – Ellex Report Full Year 2015 Preliminary Report Appendix 4E

27 August 2015

Ellex announced an operating profit before tax (PBT) of $2.6m for the year ended 30 June 2015. This represents a 100% increase on the PBT reported for the year ended 30 June 2014.

Read more

Trading Update for the Full Year Ended 30 June 2015

30 July 2015

Ellex expects to report earnings before interest, tax, depreciation and amortisation (EBITDA) of approximately $5.2 million and net profit before tax (NPBT) of approximately $2.5 million on revenues of $62.5 million for the full year ended 30 June 2015. These are preliminary and unaudited results. This compares with EBITDA of $2.9 million and NPBT of $1.3 million on revenues of $54.4 million for the prior corresponding period.

Read more

More Scientific Research Validates Clinical Effect of 2RT

19 May 2015

Ellex Medical Lasers Limited (ASX:ELX), today announced additional scientific research validating the method of action of the Company’s proprietary Retinal Rejuvenation Therapy (2RT™) in the treatment of early age-related macular degeneration (AMD).

Read more

Ellex lifts Global Market Share

6 May 2015

Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical technologies for the diagnosis and treatment of eye disease, today announced the results of an independent assessment of the global ophthalmic laser industry prepared by the respected industry consultant Market Scope®, LLC. The assessment was released in April 2015 in the report entitled “2015 Comprehensive Report on the Global Ophthalmic Laser Market”.

Read more

Ellex attending major tradeshow in China

30 March 2015

Ellex Medical Lasers Limited today announced that it will exhibit its portfolio of ophthalmic laser products for the Chinese market at the Asia Pacific Academy of Ophthalmology (APAO) convention in Guangzhou, China, from 1-4 April 2015.

Read more

Financial Report for Half-Year ended 31 December 2014

27 February 2015

Ellex Medical Lasers Limited (ASX:ELX) released its financial results for the six months ended 31 December 2014. Ellex reported a profit before tax of $1.3 million compared with $654,000 in the prior comparative period. Free cash flow from operations also increased to $1.1m compared with $0.3m in the prior corresponding period, and was significantly up on the negative $0.4m recorded for the year ended 30 June 2014.

Read more

2RT™ Makes Headline in Peer-Review Publication

5 February 2015

Ellex Medical Lasers Limited announced that its proprietary 2RT™ (Retinal Rejuvenation Therapy) has been featured on the cover of the February 2015 edition of the Journal of the Federation of American Societies for Experimental Biology (FASEB Journal).

Read more

Trading Update for the Half-Year Ended 31 December 2014

29 January 2015

Ellex Medical Lasers Limited (ASX:ELX), a world leader in medical technologies for the diagnosis and treatment of eye disease, today announced that it expects to report a profit before tax of approximately $1.3 million for the six months ended 31 December 2014.

Read more

Shareholder Update at 2014 AGM

26 November 2014

Ellex today presented its report to shareholders at it’s AGM in Adelaide. This report has been separately released to the ASX

Read more

Further Positive Scientific and Clinical Research Validating the Clinical Efficacy of 2RT for Early AMD Published

18 November 2014

Ellex announced that additional positive scientific and clinical research on the therapeutic and safety profile of the Company’s proprietary Retinal Rejuvenation (2RT™) technology has been published in the peer-review journal ‘Federation of American Societies for Experimental Biology’ (FASEB).

Read more

Canaloplasty Glaucoma Surgery Recognised as “Gold Standard” in Germany

29 October 2014

Ellex announced that patient advocacy group The German Federate Eye Association (Bundesverband Auge) has recognised Ellex’s proprietary Canaloplasty technology as the new “Gold Standard” in the surgical treatment of glaucoma.

Read more

Ellex 2RT and YAG Laser Vitreolysis Clinical Update at EURETINA/ESCRS 2014

12 September 2014

Ellex Medical Lasers Limited will spotlight its proprietary Retinal Rejuvenation Therapy (2RT™) for the treatment of early age-related macular degeneration (AMD) and YAG laser vitreolysis for the treatment of floaters during the European Society of Retina Specialists (EURETINA) and European Society of Cataract & Refractive Surgeons (ESCRS) meetings in London, UK from 13-17 September 2014.

Read more

Ellex Report Full Year 2014 Financial Results

29 August 2014

Ellex today announced an operating profit before tax of $1.3m for the year ended 30 June 2014. This is a material improvement on the operating profit of $0.14m reported last year. Net cash from operations was up 39% to $2.7 million, reflecting improved profitability and continued focus on working capital management.

Read more

Trading Update: Full Year Results for 2014 Financial Year

5 August 2014

Ellex today announced that it expects to report a Full Year Net Profit Before Tax (NPBT) of approximately $1.3 million. This compares with NPBT of $140,000 for the year ended 30 June 2013.

Read more

Commercial Sales of Proprietary 2RT™ Laser post CE Mark

8 July 2014

Ellex announced that during June it secured strategically important sales contracts for its 2RT™ retinal therapy in Europe. The devices have been installed and commissioned and the first patients have now been treated

Read more

Ellex announces further positive clinical and scientific results for 2RT treatment of early AMD

15 May 2014

Ellex today announced the 24-month follow up of the pilot study to investigate the efficacy of the Company’s proprietary Retinal Rejuvenation Therapy (2RT™) in the treatment of early Age-Related Macular Degeneration (AMD) has been released and published in a summary form at the recent Association for Research in Vision and Ophthalmology (ARVO) 2014 conference in Orlando, Florida.

Read more

Financial Results for the half-year ended 31 December 2013

27 February 2014

Ellex today announced its financial results for the six months ended 31 December 2013.

Read more

Ellex Secures CE Mark for 2RT in Treatment of Early Stage Age-Related Macular Degeneration (AMD)

26 February 2014

Ellex Medical Lasers Limited (ASX:ELX), a pioneer in medical technologies for the diagnosis and treatment of eye disease, today announced that it has secured a CE Mark (Conformité Européenne) for its proprietary Retinal Rejuvenation Therapy (2RT™) laser treatment of early Age-Related Macular Degeneration (AMD).

Read more

Trading Update for the half-year ended 31 December 2013

30 January 2014

Ellex announced that it expects to report a profit before tax of approximately $650,000 for the six months ended 31 December 2013. This result will be a material increase in the profit before tax of $59,000 reported for the six months ended 31st December 2012.

Read more

Ellex Completes Acquisition of Canaloplasty Business

6 January 2014

Ellex today announced that, pursuant to the binding agreement it entered into on 18 December 2013, it has acquired the canaloplasty business of US-based iScience Interventional, Inc., which comprises the world-leading iTRACK™ 250 catheter and suture device. On 31 December 2013 (California time) Ellex paid US$1.5 million in exchange for iScience Interventional’s canaloplasty business, including accounts receivable (approximately US$0.5m) and inventory (approximately US$0.5m). It also covers manufacturing machinery and equipment and intellectual property. Consideration for the purchase also includes an earn-out over several years based on a percentage of business revenues.

Read more

Ellex Announces Acquisition of North American Glaucoma Treatment Consumable Device Business and Completion of a $3 Million Capital Raise

20 December 2013

Ellex today announced that it has entered into a biding agreement to acquire a North American glaucoma consumable device business. Gross proceeds of A$3 million under the Placement will fund the upfront US$1.5, consideration of the acquisition while remaining funds will be applied to working capital, accelerating product development and additional debt reduction.

Read more

USA SLT Glaucoma Laser Update

12 November 2013

Ellex today announced that it has recorded a solid improvement in group sales during the four months ended 31 October 2013 compared with the prior comparable period in the 2013 financial year. Of particular significance was a material improvement in sales in the USA. In July 2013 Ellex commenced sales of its world-leading SLT glaucoma laser range (Tango™ and Solo™) in the USA. Interest from ophthalmologists in the USA has been strong, with our US business recording key SLT sales at a number of sites. This, combined with the positive impact of additional new product introductions and the lowering of the Australian Dollar relative to the US Dollar, has resulted in a boost to US sales of approximately 80% compared…

Read more

Ellex Announces Release of Positive Pilot Study Results for 2RT Treatment of Early AMD

14 October 2013

Ellex Medical Lasers Limited (ASX:ELX), a pioneer in medical technologies for the diagnosis and treatment of eye disease, today announced that the results of a pilot study to investigate the efficacy of the Company’s proprietary Retinal Rejuvenation Therapy (2RT) in the treatment of early Age-Related Macular Degeneration (AMD) have been released and published in the peer-reviewed, scientific publication Clinical & Experimental Ophthalmology.

Read more

Ellex Secures US Government Qualification for SLT Glaucoma Laser Products

26 September 2013

Ellex Medical Lasers Limited (ASX:ELX), a pioneer in medical technologies for the diagnosis and treatment of eye disease, today announced that its portfolio of industry-leading SLT glaucoma lasers has been qualified for inclusion on its US Government Services Administration (GSA) contract. Effective 1 October 2013, the Company’s SLT lasers can be sold to US government medical facilities in the USA and around the world.

Read more

Ellex Completes Successful Placement to Raise $3.3 Million

19 September 2013

Ellex has successfully completed a placement to institutional and sophisticated investors, raising gross proceeds of approximately A$3.3 million (Placement).

Read more

Ellex Achieves Key Milestones in Clinical Trial Program for 2RT

4 September 2013

Ellex today announced several key milestones in the Company’s clinical trial program for its proprietary Retinal Rejuvenation Therapy (2RT™) in the treatment of Early Age-Related Macular Degeneration (AMD). Currently, there are no approved treatments for the early form of AMD, which represents a considerable market opportunity for Ellex.

Read more

Trading Update: Full-Year Result for 2013 Financial Year

29 August 2013

Ellex today announced its audited financial results for the full-year ended 30 June 2013. A net profit before tax (NPBT) of $0.14 million was reported on revenues of $42.8 million. This result was down from the $1.1 million NPBT on revenues of $47.8 million achieved for the year ended 30 June 2012. Cash from operations increased from $1.8 million to $1.9 million during the period.

Read more

Trading Update: Full-Year Result for 2013 Financial Year

14 August 2013

Ellex today announced that it expects Net Profit Before Tax (NPBT) to be between $100,000 and $200,000 for the year ended 30 June 2013. This compares to NPBT of $1.1 million for the year ended 30 June 2012.

Read more

Ellex Secures US FDA Approval for 2RT in Treatment of Diabetic Eye Disease

18 July 2013

That it has secured Ellex today announced that it has secured US FDA 510(k) approval for its proprietary Retinal Rejuvenation Therapy (2RT™) in the treatment of Clinically Significant Macular Edema (CSME), the most common form of diabetic eye disease which can result in legal blindness.

Read more

Ellex Launches Glaucoma Laser Platform in the USA

11 July 2013

Ellex today announced the launch of its proprietary SLT (selective laser trabeculoplasty) technology in the United States.

Read more

Appointment of Independent Directors

17 May 2013

Ellex today announced the appointment of Dr. Meera Verma and Mr. Rahmon Coupe to the Board of Ellex Medical Lasers Limited as independent non-executive directors.

Read more

Resignation of Malcolm Plunkett as Director

4 March 2013

Ellex today announced the resignation of Mr Malcolm Plunkett as a Director of the Company. Throughout his four and a half year tenure as a Director, Mr Plunkett has been a full time executive in the business responsible for research and development and has made a significant contribution to the business. He will continue in this executive role concentrating on bringing the 2RT project through to market release and managing the business’s research portfolio.

Read more

Ellex Announces Half-Year Results for 2013 Financial Year

27 February 2013

Ellex today announced today announced its financial results for the half-year ended 31 December 2012. Consistent with the earnings guidance issued on 30 January 2013, revenue for the half-year was $22.0 million, 16% down on prior comparable period. As a result half-year profit was $59,000. Notwithstanding this reduced profit, improved inventory and purchasing management resulted in a significant improvement in cash generated from operations to $1.79 million for the six months to 31 December 2012, compared with $71,000 for the prior comparable period.

Read more

Trading Update: Half-Year Result 2013 Financial Year

30 January 2013

Ellex today announced that it expects profit before tax to be between $50,000 and $100,000 for the six months ended 31 December 2012. This compares to a profit before tax of $949,246 for the six months ended 31 December 2011.

Read more

Appointment of Company Secretary

7 January 2013

Ellex today announced the appointment of Maria Maieli as Company Secretary.

Read more

Results of 2012 Annual General Meeting Incorporating Proxy Results

29 November 2012

Ellex confirms in accordance with Listing Rule 3.13.2, the results for each of the resolutions put to the Annual General Meeting held at 2:00pm on Thursday 29 November 2012.

Read more

Ellex Announces Commencement of Patient Recruitment for Clinical Trial of Laser for Treatment of Early Stage Age-Related Macular Degeneration

23 November 2012

Ellex today announced that the Centre for Eye Research Australia (CERA) has commenced patient recruitment in a multi-centre clinical trial to validate the clinical efficacy of Retinal Rejuvenation Therapy (Ellex 2RT™) in the treatment of Early Age-Related Macular Degeneration (AMD).

Read more

Ellex Launches New Ophthalmic Products at American Academy

7 November 2012

Ellex today announced that it will be launching a suite of new ophthalmic products at the American Academy of Ophthalmology (AAO) congress in Chicago, Illinois from 10 to 13 November, 2012.

Read more

Ellex Secures Contract Manufacturing Agreement with Signostics Limited

1 November 2012

Ellex today announced that it has been awarded a contract by Signostics Limited, a pioneer in the development of hand-held medical ultrasound devices, to manufacture the critical sub-assembly of the Signostics ultrasound device, Signos RT.

Read more

Ellex Announces Full-Year Result for 2012 Financial Year

30 August 2012

Ellex today announced its audited financial results for the full-year ended 30 June 2012. A concerted effort to drive bottom line improvement, combined with strong sales performance in the Company’s direct markets of the USA and Australia, delivered a Net Profit Before Tax (NPBT) of approximately $1.1 million.

Read more

Trading Update: Large Turnaround to Profit in FY12

23 July 2012

Ellex today announced an expected $2 million turnaround in Net Profit Before Tax (NPBT) and a 10% increase in revenue during the year ended 30 June 2012 compared with the prior corresponding period. Improved bottom line focus, coupled with improved sales in USA and Australia are expected to deliver a NPBT of $1.1 million on revenues of $47.5 million for the year ended 30 June 2012.

Read more

Ellex Secures CE Mark for Breakthrough Retinal Rejuvenation Therapy

18 July 2012

Ellex today announced that it has secured a CE Mark (European Conformity) for its breakthrough Retinal Rejuvenation Therapy (Ellex 2RT™). This world-first nano-pulse retinal laser therapy ushers in a new era of pain-free and damage-free retinal treatment.

Read more

Ellex Acquires Minority Interest in Ellex Australia Pty Ltd

28 February 2012

Ellex today announced it had acquired on commercial terms the 20% minority interest in Ellex Australia Pty Ltd hitherto held by a former manager who has retired from the business. The acquisition means that Ellex Australia Pty Ltd is now a wholly-owned subsidiary of Ellex Medical Lasers Limited.

Read more

Ellex Announces Half-Year Results for 2012 Financial Year

23 February 2012

Ellex today announced its financial results for the half-year ended 31 December 2011. Improved sales performance in the Company’s direct markets of America and Australia, combined with continued operating efficiencies, has led to an increase in profit before tax of 50% compared with the prior corresponding period.

Read more

Trading Update: Half-Year Result 2012 Financial Year

2 February 2012

Ellex today announced that as a result of improved revenues and operating cost reductions, the Company expects profit before tax for the six months ended 31 December 2011 to be approximately 50% higher than the profit before tax for the prior comparative period.

Read more

Results of 2011 Annual General Meeting

24 November 2011

Ellex is pleased to announce the results of resolutions put to the 2011 Annual General Meeting.

Read more

Ellex Launches Innovative Medical Laser Technology onto Global Market

20 October 2011

Ellex today announced that it will introduce the innovative Integre Pro™ laser platform for the treatment of retinal disease at the upcoming meeting of the American Academy of Ophthalmology (AAO).

Read more

Resignation of non-executive Director

23 September 2011

Ellex today advises that Professor John Marshall has resigned as a non-executive director of the Board.

Read more

Ellex Announces Full-Year Results for 2011 Financial Year

30 August 2011

Ellex today announced its unaudited financial results for the full-year ended 30 June 2011. As indicated in the Company’s trading update on 21 July 2011, a material strengthening of the Australian dollar, compounded by costs associated with closure of the Company’s US-based manufacturing facility, negatively impacted earnings and operating performance during the 2011 financial year.

Read more

Trading Update: Full-Year Result 2011 Financial Year

21 July 2011

Ellex today announced that as a result of reduced revenues in the 2011 financial year, the Company expects the operating result to be breakeven or a small loss.

Read more

Ellex to Deliver Improved Manufacturing Efficiencies and Cost-Savings

21 June 2011

Ellex today announced plans to consolidate the manufacture of all Ellex laser and ultrasound products out of its state-of-the-art manufacturing facility in Adelaide, Australia.

Read more

Positive Ellex 2RT Data Demonstrates Efficacy in Treatment of Early AMD

3 May 2011

Ellex today announced milestone clinical results for its breakthrough Retinal Regeneration Therapy (Ellex 2RT) for the treatment of Early Age-Related Macular Degeneration (AMD).

Read more

Company Update – New CEO and Executive Appointment

31 March 2011

Ellex today announced the appointment of Tom Spurling as Group CEO, effective immediately. Mr. Spurling will replace outgoing CEO, Simon Luscombe. In parallel with this appointment Yukitaka Isoda has been promoted to the position of President, Global Operations, to support the Company’s global sales and distribution platform.

Read more

Ellex to Deliver New Diagnostic Ultrasound Mode at ASCRS

23 March 2011

Ellex today announced that it will introduce a new diagnostic ultrasound mode for its leading Eye Cubed™ system at the upcoming meeting of the American Society of Cataract and Refractive Surgeons Meeting.

Read more

Ellex Enters Ophthalmic Lens Market, Secures Distribution Deal with STAAR Surgical

10 March 2011

Ellex today announced that it will expand its presence into the ophthalmic lens market through a strategic partnership with global lens manufacturer STAAR Surgical.

Read more

Ellex FY2011 Half-Year Results

24 February 2011

Ellex today announced its audited financial results for the half-year ended 31 December 2010. Despite achieving improved operating efficiencies during the period, a softening in demand in key markets, compounded by a material strengthening of the Australian dollar, negatively impacted earnings during the first half of the 2011 financial year.

Read more

Trading Update: Half-Year Result 2011 Financial Year

7 January 2011

Trading Update: Half-Year Result 2011 Financial Year Ellex today announced that, due to a softening in sales demand and the materially stronger Australian dollar, it expects its profit result for the half-year ending 31 December 2010 to be lower than that achieved in the prior comparable period.

Read more

Results of 2010 Annual General Meeting

25 November 2010

Ellex is pleased to announce the results of resolutions put to the 2010 Annual General Meeting.

Read more

Ellex to Preview New Laser for Treatment of AMD

17 November 2010

Ellex today announced that it will preview a prototype of its new Retinal Regeneration Therapy (Ellex 2RT™) laser at the upcoming Royal Australian and New Zealand College of Ophthalmology (RANZCO) meeting in Adelaide, Australia, from Sunday 21 November.

Read more

Ellex Secures Additional Distribution Deal with CenterVue

3 November 2010

Ellex today announced that it has secured a second distribution deal with Italian-based CenterVue to market the DRS retinal camera in the United States. This follows the Company’s recent announcement that it had secured distribution rights for CenterVue’s MAIA™ fundus perimetry system in the United States and Australia.

Read more

Ellex Secures Major Distribution Deal with CenterVue

12 October 2010

Ellex today announced that it will expand its presence in the ophthalmic diagnostics market through a strategic partnership with leading medical device manufacturer CenterVue SpA.

Read more

Ellex Full Year Results 2010

26 August 2010

Ellex announced today a Net Profit Before Tax (NPBT) of $3.6 million for the year ended 30 June 2010, a 16% increase compared to $3.1 million in the previous year.

Read more

Profit Upgrade Guidance: Ellex 2010 Financial Year

18 August 2010

Ellex announced today a profit upgrade guidance with full year Net Profit Before Tax (NPBT) for 2010 expected to be in the vicinity of $3.5 million, a 13 percent improvement compared to $3.1 million in the previous year, subject to final audit.

Read more

Ellex 2RT Studies Demonstrate Clinical Efficacy in Treatment of AMD and Diabetic Retinopathy

7 May 2010

Ellex announced today major positive clinical results for its world leading laser Retina Regeneration Therapy (Ellex 2RT™) for the treatment of Age-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR), two conditions that usually result in irreversible blindness for sufferers.

Read more

Ellex to Present New Clinical Results for Ellex 2RT at ARVO 2010

3 May 2010

Ellex announced today that initial clinical results of two new studies for Ellex Retina Regeneration Therapy (Ellex 2RT™) will be presented at the Association for Research in Vision and Ophthalmology’s (ARVO) 2010 Annual Meeting, which takes place 2-6 May in Fort Lauderdale.

Read more

Ellex Secures Sublicense Agreement for Ellex 2RT

12 April 2010

Ellex today announced that it has sublicensed Patent No. 5,549,596, effectively enabling the Company to bring Ellex 2RT(TM) technology to market in the US…

Read more

Ellex FY2010 Half Year Results and Highlights

25 February 2010

Ellex today announced its audited financial results for the half year ended 31 December 2009. The Company delivered a strong performance during the first half of the 2010 financial year, achieving solid underlying profitability and positive cash flow despite a challenging economic environment.

Read more

Market Update

9 February 2010

Ellex today announced that the Company’s earnings performance in the first half of the 2010 financial year was better than anticipated, with unaudited Earnings Before Interest Tax and Depreciation (EBITDA) of $2.9 million, up 12% compared to the period ending December 2008 (excluding the impact of non-recurring items in the comparative period).

Read more

Ellex Delivers Industry’s First Integrated Yellow Laser

22 January 2010

Ellex today announced the launch of a new yellow laser photocoagulator, Integre Yellow™, at the 33rd Annual Meeting of the Japanese Society of Ophthalmic Surgeons (JSOS) in Tokyo.

Read more

Trading Update

17 December 2009

Ellex announced today that world wide sales of the Company’s products have softened in the second quarter. As a result, it is expected that the Company’s budget targets will not be met for the half year ending on 31 December 2009.

Read more

Results of 2009 Annual General Meeting

8 December 2009

Ellex is pleased to announce the results of resolutions put to the 2009 Annual General Meeting.

Read more

Ellex 2RT™ Research Program Awarded Government Grant

13 November 2009

Ellex announced today that the Ellex 2RT™ Research Program has been awarded a $0.54 million Victorian Government grant.

Read more

Westpac Banking Facility Extended to 30 September 2011

10 November 2009

Ellex today announced that it has extended its current banking facility with Westpac Banking Corporation. Under the agreement, Ellex has refinanced its core debt facility with Westpac to 30 September 2011.

Read more

Ellex to Deliver New Generation Ultrasound at AAO

23 October 2009

Ellex today announced that it will introduce the latest version of the Eye Cubed diagnostic ultrasound system at the annual meeting of the American Academy of Ophthalmology (AAO), October 24 – 27, 2009 in San Francisco.

Read more

Ellex Releases Unaudited FY09 Year End Result

27 August 2009

Ellex today announced its financial results for the year ended 30 June 2009.

Read more

Ellex Reaches Milestone in SLT Laser Sales

10 June 2009

Ellex today announced that it now has in place more than 1,000 SLT (Selective Laser Trabeculoplasty) laser systems on a global basis.

Read more

Banking Facility Extended

13 May 2009

Ellex today announced that the company’s banker, Westpac, has reviewed Ellex’s financial position and have issued a finance offer along similar lines to the existing arrangements that extends the facility until 31 August 2009, when it will again be reviewed.

Read more

Ellex Appoints General Manager, Ellex Australia

1 April 2009

Ellex today announced the appointment of John Edwards as General Manager of the Company’s Australian sales subsidiary, Ellex Australia.

Read more

Ellex Reports Record First Half Revenue

26 February 2009

Ellex today announced its financial results for the half year ended 31 December 2008. The result demonstrates continued growth in a challenging economic environment.

Read more

Ellex Market Update

19 December 2008

Ellex announced on the 31 October 2008 that foreign exchange (FOREX) hedging contracts entered into by the Company in July 2008 will impact the profitability of the Company in the current financial year.

Read more

Results of 2008 Annual General Meeting

1 December 2008

Ellex announced today the results of resolutions put to the 2008 Annual General Meeting.

Read more

Ellex Announces Non-Renounceable Pro-Rata Rights Issue to Shareholders

1 December 2008

Ellex announced today a non-renounceable pro-rata Rights Issue to shareholders of Ellex.

Read more

Ellex Announces Six-Month Results on Retina Regeneration Therapy

10 November 2008

Ellex today announced the six-month clinical study results for the groundbreaking treatment Retina Regeneration Therapy (Ellex 2RT™) at the annual meeting of the American Academy of Ophthalmology.

Read more

Ellex to Preview New Multi-Color Photocoagulation Laser at AAO

4 November 2008

Ellex today announced that it will preview a new, multi-color photocoagulation laser, Integre Pro™, at the upcoming American Academy of Ophthalmology (AAO), November 8-11, 2008 in Atlanta.

Read more

Ellex to Review Foreign Exchange Hedging Contracts

31 October 2008

Ellex announced today that the impact of Foreign Exchange (FOREX) hedging contracts entered into by the Company in July 2008 are likely to temper profits for this financial year

Read more

Appointment of New Chief Financial Officer, Company Secretary

28 October 2008

Ellex announced today the appointment of Melanie Young as Chief Financial Officer (CFO), effective immediately. Ellex also announced the appointment of Giuseppe Canala as Company Secretary. These appointments follow the departure of Tony Mitchell.

Read more

Appointment of New CEO

22 October 2008

Ellex announced today the appointment of Mr. Simon Luscombe as Group CEO, effective immediately. This follows the departure of Mr. Kevin McGuinness.

Read more

Director and Advisor Appointments

17 October 2008

Ellex announced today the appointment of Mr. Giuseppe Canala and Mr. Malcolm Plunkett to its board of directors. Ellex also announced the appointment of Mr. Warwick Kitt as an advisor to the company.

Read more

Revised Date of Annual General Meeting

15 October 2008

Ellex wishes to advise that it has revised the date for the holding of the 2008 Annual General Meeting.

Read more

Notice of Members’ Resolution at General Meeting

24 September 2008

Ellex wishes to advise that it has received an appropriately authorised Notice of Members’ Resolution under section 249N of the Corporations Act 2001 (Cth) from Intertec Healthcare Partners, L.P. and Dr Matthias Maus giving notice that they propose to move the following motion at the Company’s Annual General Meeting.

Read more

Ellex FY08 Year End Results

27 August 2008

Ellex today announced its financial results for the year ended 30 June 2008.

Read more

Market Update – Position of CEO; Update on Outlook FY08

25 June 2008

Ellex advises today that CEO Mr Peter Falzon has ceased employment with the Company with immediate effect.

Read more

Outcome of Routine Tax Audit

14 May 2008

Ellex advises today that the Australian Taxation Office (ATO) routine audit of the Company has been completed with no adjustments required.

Read more

Update on Outlook for FY08 Result

2 May 2008

Ellex announced today that due to the difficult economic environment, sales growth and pre-tax earnings for the 2008 financial year are not expected to be as strong as previously advised.

Read more

Ellex Appoints Tony Mitchell as CFO

3 March 2008

Ellex announced today the appointment of Tony Mitchell as CFO and company secretary.

Read more

Ellex FY2008 Half Year Results

26 February 2008

Ellex announced today its financial results for the half year ended 31 December, 2007

Read more

Update on FY08 First Half Result and Outlook for the Year

31 January 2008

Ellex announced today that revenue growth in the first half of the 2008 Financial Year would exceed market guidance of 15% over the comparable period in 2007 with approximately 18% achieved.

Read more

Results of 2007 Annual General Meeting

28 November 2007

Ellex announced today the results of resolutions put to the 2007 Annual General Meeting.

Read more

Ellex Appoints Warwick Kitt as a Director of Ellex Australia Pty Ltd

23 November 2007

Ellex announced today that Warwick Kitt has joined the Board of Ellex Australia Pty Ltd.

Read more

Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema

10 November 2007

Ellex today announced clinical results of an ongoing study for non-thermal Retina Regeneration Therapy (Ellex 2RT™).

Read more

Ellex Announces New Retina Regeneration Therapy to be Presented at the AAO

1 November 2007

Ellex today announced that the initial results of treating patients with Retina Regeneration Therapy (Ellex 2RT™) will be presented by Peter Hamilton MD, FRCOph at the annual meeting of the American Academy of Ophthalmology.

Read more

John Marshall and Kevin McGuinness Appointed to Ellex Board

15 October 2007

Ellex announced today the appointment of Professor John Marshall and Kevin McGuinness to its board of directors to underpin the growth strategy of the company.

Read more

Ellex FY2007 Year End Results

23 August 2007

Ellex today announced its financial results for the year ended 30 June 2007.

Read more

Ellex Appoints VP of U.S. Sales and Announces U.S. Expansion

2 August 2007

Ellex announced today that effective September 1, 2007 it has appointed Ms Christin Harris as Vice President of U.S. Sales to lead its sales expansion in the United States.

Read more

Ellex Raises $5.5 Million Through Placement

26 June 2007

Ellex announced today that it raised $5.5 million through the placement of 6.5 million ordinary shares at a price of A$0.85 per share.

Read more

Ellex Gains US FDA Approval for 30XL Laser Slit Lamp

23 April 2007

FDA approval of the 30XL laser slit lamp represents another milestone in Ellex’s stated strategy to be the leading brand of lasers to treat glaucoma, cataract and retinal conditions.

Read more

Ellex Enters Chinese Ophthalmic Laser Market

5 April 2007

Ellex has appointed GT Medical, a division of Guotong Holdings Company Limited as its exclusive distributor in China.

Read more

First Half FY07 Results

27 February 2007

Results confirm that Ellex is gaining market share as a result of investments made in new products and distribution. Revenues grew by 26%, exceeding the estimated market growth rate of 5% per year, to $21.2 million.

Read more

Awarded AusIndustry Grant

14 February 2007

Awarded $1.9M AusIndustry Grant to Conduct AMD Laser Research.

Read more

Ellex Acquires Innovative Imaging

4 December 2006

Ellex announced today that it has acquired Innovative Imaging, Inc., a profitable U.S.-based leader in the design and manufacture of ophthalmic diagnostic ultrasound systems.

Read more

Chairman’s Address to Annual General Meeting

2 November 2006

Read more

Ellex Establishes Direct Sales Channel in Australia

3 October 2006

Ellex commences trading of Ellex Australia Pty Ltd as a direct sales subsidiary that will sell the Ellex range of lasers direct to Australian ophthalmologists.

Read more

Full Year FY2006 Results

23 August 2006

Ellex returns to profitability on the back of strong revenue growth.

Read more

Full Year FY2006 Results Presentation

23 August 2006

Full Year FY2006 Results Presentation

Read more

Ellex to Acquire Coherent Lasers Australia

21 August 2006

Ellex to market its ophthalmic lasers directly to ophthalmologists in Australia, New Zealand and the South Pacific

Read more

Ellex Appoints US Laser Industry Veteran as VP Operations

25 July 2006

Herbert Pummer PhD, an accomplished laser industry veteran, appointed as Vice President of Operations.

Read more

Ellex Appoints First Direct Salesperson in US

5 June 2006

Ellex moves to direct sales in US with the appointment of Timothy Broome as Senior Territory Manager.

Read more

Ellex Appoints New Position of Chief Operating Officer

27 April 2006

Kevin McGuinness appointed to the new position of Chief Operating Officer (COO).

Read more

Ellex Receives FDA Clearance for Red/Green Photocoagulator

11 April 2006

Integre Duo, the industry’s first solid-state red/green photocoagulator, receives 510(k) clearance.

Read more

Ellex to Present at Citigroup Microcap Conference

30 March 2006

April 4, 2006, Sydney, Australia

Read more

Ellex Introduces New Retina Laser at the ASCRS Annual Meeting

18 March 2006

Ellex to introduce the Integre Duo, the world’s first solid-state red and green photocoagulator, today at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in San Francisco.

Read more

Ellex Announces Rebranding and Shifts Focus to Direct Marketing of its Ophthalmic Lasers

16 March 2006

Global Headquarters, led by CEO, to move to SF Bay Area.

Read more

First Half FY06 Results

1 March 2006

Ellex today reported a Net Profit after Tax of A$1.0 million for the first half of FY06, up significantly on the comparable period last year.

Read more

Half Year FY2006 Results Presentation

1 March 2006

Read more

Ellex Sells Property for $4.43 Million

19 January 2006

Ellex today announced that the company had signed a contract for the sale of its building in Adelaide for a price of $4.43 million.

Read more

Chairman’s Address

29 November 2005

Ellex Chairman’s Introduction to AGM 2005

Read more

AusIndustry Extends Research and Development Grant

15 November 2005

AusIndustry has approved an additional grant of $0.4 million

Read more

Impact of Transition to International Financial Reporting Standards (IFRS)

7 November 2005

Ellex wishes to advise that it has completed a detailed review of the impact of the transition from Australian Accounting Standards to IFRS.

Read more

Ellex to Seek Expressions of Interest for Adelaide Property

7 November 2005

Ellex wishes to advise that it has engaged Knight Frank (Adelaide) to seek expressions of interest for the sale of its head quarters located at 82 Gilbert Street, Adelaide.

Read more

Preliminary Final Report – 12 Months to 30 June 2005

8 September 2005

Ellex today announced the Company had achieved a satisfying full year result in line with expectations and has completed a restructuring plan expected to result in strong performance in FY2006.

Read more

Ellex Announces Board Changes

25 July 2005

Ellex Medical announced today that David Lindh had retired from his position as Chairman of the Board of Ellex Medical after 5 years of service and resigned as a Director.

Read more

Ellex Announces Solitaire Release and R&D Reorganisation

20 June 2005

Ellex Medical Lasers Limited (ELX) advises that following the successful conclusion of the development phase for the Solitaire photocoagulator and the introduction into production, engineering and product development will be consolidated back into Adelaide.

Read more

Resignation of Director

19 April 2005

Ellex Medical Lasers Limited (Ellex) wishes to advise that Dr Keith Robert Johnson has resigned as a Director of Ellex.

Read more

Ellex Announces Restructure of Senior Management in Line with Corporate Strategy

28 February 2005

Ellex Medical today announced that it had restructured the senior management team, reflecting the Company’s growth strategy, now in it’s second year.

Read more

December 2004 Half Year Release

18 February 2005

Ellex Medical today announced a modest growth in revenues for the six months to December 2004. The Company’s planned strategy of reinvesting into product development and distribution resulted in a modest profit, on a pre-goodwill basis.

Read more